ReviewBiomicrofluidics2021
From cell spheroids to vascularized cancer organoids: Microfluidic tumor-on-a-chip models for preclinical drug evaluations.
Review in Biomicrofluidics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Microfluidic-Driven Assembly of RNA Nanocomplexes: Design, Process Control and Translational Perspectives in Oncology.Pharmaceutics · 2026Review
- Vascularized Tumor-on-a-Chip Model as a Platform for Studying Tumor-Microenvironment-Drug Interaction.Macromolecular bioscience · 2025Review
- Machine learning-assisted exploration of multidrug-drug administration regimens for organoid arrays.Science advances · 2025Article
- ODSEI Chip: An Open 3D Microfluidic Platform for Studying Tumor Spheroid-Endothelial Interactions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- "ArmedFrontiers in cell and developmental biology · 2025Review
- Application and development of Organ-on-a-Chip technology in cancer therapy.Frontiers in oncology · 2025Review
- Recent Developments in Glioblastoma-On-A-Chip for Advanced Drug Screening Applications.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Revolutionizing immune research with organoid-based co-culture and chip systems.Clinical and experimental immunology · 2024Review
- Magnetically Integrated Tumor-Vascular Interface System to Mimic Pro-angiogenic Endothelial Dysregulations for On-Chip Drug Testing.ACS applied materials & interfaces · 2024Article
- Acoustofluidic Actuation of Living Cells.Micromachines · 2024Review
- 3D cell culture models in research: applications to lung cancer pharmacology.Frontiers in pharmacology · 2024Review
- Advances in the Model Structure of In Vitro Vascularized Organ-on-a-Chip.Cyborg and bionic systems (Washington, D.C.) · 2024Article
- New Strategy for Promoting Vascularization in Tumor Spheroids in a Microfluidic Assay.Advanced healthcare materials · 2023Article
- Microfluidic Droplet-Assisted Fabrication of Vessel-Supported Tumors for Preclinical Drug Discovery.ACS applied materials & interfaces · 2023Article
- Hierarchical Vessel Network-Supported Tumor Model-on-a-Chip Constructed by Induced Spontaneous Anastomosis.ACS applied materials & interfaces · 2023Article
- High-throughput fabrication of cell spheroids with 3D acoustic assembly devices.International journal of bioprinting · 2023Article
- Recent Advances of Organ-on-a-Chip in Cancer Modeling Research.Biosensors · 2022Review
- Engineering complexity in human tissue models of cancer.Advanced drug delivery reviews · 2022Review
- Performance of nanoparticles for biomedical applications: TheBiophysics reviews · 2022Review
- Microfluidic vascular models of tumor cell extravasation.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Chemotherapy is one of the most effective cancer treatments. Starting from the discovery of new molecular entities, it usually takes about 10 years and 2 billion U.S. dollars to bring an effective anti-cancer drug from the benchtop to patients. Due to the physiological differences between animal models and humans, more than 90% of drug candidates failed in phase I clinical trials. Thus, a more efficient drug screening system to identify feasible compounds and pre-exclude less promising drug candidates is strongly desired. For their capability to accurately construct
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.